Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667004 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
- 1
- Study location
NCT00667004 is a Phase 2 study of Dry Eye Disease that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 183 participants, below the 249-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00667004, a Phase 2 study of Dry Eye Disease, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
- 1
- Study location
Study Summary
Efficacy study of ecabet ophthalmic solution in dry eye disease
Conditions Studied
Interventions
- DRUG placebo
- DRUG ecabet ophthalmic solution
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2008-03-22 |
| Est. Completion | 2008-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667004
The ClinicalTrials.gov registry entry for NCT00667004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 249-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (27% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00667004 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00667004 about?
NCT00667004 is a clinical study titled "Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease". Efficacy study of ecabet ophthalmic solution in dry eye disease
What is the current status of trial NCT00667004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2008-03-22. Estimated completion is 2008-09-12.
What conditions does trial NCT00667004 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT00667004?
The interventions under investigation include: placebo (DRUG), ecabet ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00667004?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00667004 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.